Thales Expands Technology Partner Ecosystem to Accelerate Enterprises’ Cloud and Digital Transformation Initiatives
Enterprises can now reduce cyber risk and secure their digital transformation initiatives in new markets including Blockchain, Cloud, DevOps, IoT and Code Signing as Thales unveils an expansion of its data protection ecosystem to more than 300 technology partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200812005038/en/
(Photo : Thales)
Through these expanded technology integrations, which now include more than 500 IT products and services, Thales is enabling more organisations to integrate its data encryption, hardware security modules, key management and access management technologies with their existing IT infrastructure and cloud services to protect applications, data and identities. This will empower organisations to implement centralised data protection and access management controls for the whole customer journey.
“The use of the cloud and digital transformation is now the cornerstone of any modern company,” said Sebastien Cano, Senior Vice President for Cloud Protection and Licensing Activities at Thales. “Vitally though, those that are truly leading the way are doing so by integrating security by design into their processes from the start. By integrating our data protection products and services with hundreds of technology partners, we can ensure customers and their sensitive data are protected throughout their entire transformation journey and remain at the forefront of their industries.”
Thales is collaborating with leading companies that are driving the adoption of Blockchain technology by integrating its Luna Network Hardware Security Modules (HSM) as the root of trust to secure blockchain-based transactions. Recently, Thales integrated its Luna Network HSM with CLS Group – a dedicated crypto processor that is specifically designed for the protection of the crypto key lifecycle – and Hyperledger – a multi-project open source collaborative effort hosted by The Linux Foundation, created to advance cross-industry blockchain technologies.
Enabling Secure Cloud Transformation
Today, organisations on average use 29 cloud services for their collaboration, computing, customer relationship management and storage needs. Thales is helping companies secure the move to the cloud with cloud key management and access management solutions that integrate with the most widely used cloud platforms and services including AWS, Azure, Box, Office365 and Slack.
Thales’s SafeNet Trusted Access enables organisations to modernise their IT and Identity and Access Management (IAM) schemes, as part of their cloud transformation initiatives. For example, integrations with IGA vendors such as SailPoint enable secure identity governance and identity management workflows; Security for privileged users is achieved by securing PAM solutions such as BeyondTrust, at the access point; and continuous authentication and access control is enabled by working with CipherCloud’s CASB solution.
Securing Hybrid IT Environments
While organisations are rapidly adopting cloud services and moving infrastructure to the cloud, the majority are maintaining hybrid IT environments. One of the key challenges they face in doing so is bridging between modern and cloud IAM schemes. To this end, SafeNet Trusted Access’s integration with F5 BIG IP enables enterprises to implement smart SSO for cloud services while securing on premises legacy applications.
“Data and applications are fast becoming the lifeblood of any organisation, no matter the industry,” said John Morgan, VP & GM Security at F5. “For any customer to truly take advantage of this digital transformation, applications and their underlying data must be secure. By joining the Thales partner ecosystem, we are continuing our long history of collaboration to help customers achieve positive business outcomes through secure digital transformation.”
Enabling Trust for DevOps
Digital certificates play an integral role in DevOps workflows, securing authentication across users, devices and applications. The secure identities and certificates establish trust within enterprise infrastructure, pipeline, code and containers. Thales has expanded its DevOps technology partners to include Red Hat, HashiCorp, Kubernetes, VMWare Tanzu, Docker and Google for secure DevOps to enable customers to realise the benefits of automation, scale, & cloud native applications and digital transformation.
Securing the Identities and Data in IoT
In order to secure, manage and authenticate the billions of identities that will be created with the Internet of Things, Thales has recently expanded integrations for its HSMs, Data Encryption and Key Management solutions with leading providers of IoT security solutions such as Cisco, Microsoft, DigiCert, Sectigo, GlobalSign, KeyFactor and Venafi to help organisations secure the billions of identities that will be created over the next few years.
Code Signing becomes an essential service for businesses
Code signing has emerged as an essential ingredient to doing business for virtually any organisation that distributes code to customers and partners. Code signing verifies who the publisher of a specific set of code is and attests that it has not been modified since it was signed. Certificates delivered along with software that has been signed are a key way for users to determine whether software originates from a legitimate source before installing. Today, many software marketplaces, including mobile app stores, require code to be compliant with specific digital signing requirements.
One of those mandates is for applicants to generate and store their private key using a FIPS 140-2 Level 2 certified hardware solution. This can be a Hardware Security Module (HSM) that protects the identity, whether it is the server, virtualization server or the user. Thales' HSMs take the security one step further by storing the signing material in a hardware device, thus ensuring authenticity and integrity of a code file. Thales code signing partners include Adobe, DigiCert, Garantir GlobalSign, Keyfactor, Microsoft and Venafi.
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
Thales, Media Relations
+33 (0)6 44 12 16 35
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis26.1.2021 14:00:00 CET | Press release
Mundipharma and Cidara Therapeutics today announced that the European Commission (EC) has now adopted the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) recommendation to grant Orphan Drug Designation (ODD) to rezafungin, a novel, once-weekly echinocandin, for the treatment of invasive candidiasis (IC).4 The EMA considers ODD status for medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than five per 10,000 people in the EU.5 It is estimated that IC occurs in around 0.84 per 10,000 people in the EU,6 and mostly affects hospitalised, immunocompromised or critically ill patients.2 IC continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. Despite a number of available treatments, mortality rates are as high as 40%.3 IC is characterised as a severe, life-threatening systemic Candida infection of the bloods
Software Industry: Nexway™ Reinforces the Customer Experience Capabilities of its Monetize Personalized Growth Platform26.1.2021 14:00:00 CET | Press release
Nexway, a leading software and service company for e-commerce and payments, is very excited to launch the latest features on its personalized growth platform Nexway Monetize, moving forward in its mission to expand the online footprint and sales potential of software vendors, games publishers and service providers across 140 countries around the world. In today’s uncertain business environment, the e-commerce and payment leader is looking to leverage its best technologies to offer a seamless purchase experience, helping its clients to remain flexible in their strategic approach to e-commerce. Nexway‘s teams are driving versatility, flexibility, and frictionless features to conquer new markets and expand into vertical sectors linked to customer monetization, subscriptions, and B2B sales management. Nexway also intends to continue growing thanks to its agility, expertise, and high level of the customer purchase experience. "Customer experience is a constantly moving target, changing to m
Velodyne Lidar Signs Multi-Year Sales Agreement with Emesent26.1.2021 13:00:00 CET | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced a multi-year sales agreement to provide Puck LITE™ sensors to Emesent, a world-leader in drone autonomy, lidar mapping and data analytics. Emesent is using Velodyne’s lidar sensors to power its award-winning Hovermap mobile scanning system for mapping hazardous and GPS-denied environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005229/en/ Emesent’s Hovermap, equipped with a Velodyne Puck LITE™ sensor, has a colorization feature for its 3D point clouds that brings additional context for visualization and analysis. (Photo: Emesent) Hovermap, which can be hand-held or mounted to a drone, uses Puck LITE lidar as its primary perception and mapping sensor. Equally capable above ground or underground, indoors or out, Hovermap combines advanced collision avoidance and autonomous flight technologies to map challenging, inaccessible areas. Hovermap has a coloriza
Allurion Technologies Launches Virtual Care Suite to Transform the Consumer and Provider Experience26.1.2021 13:00:00 CET | Press release
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fallurion.com%2F&esheet=52366910&newsitemid=20210126005074&lan=en-US&anchor=Allurion%26%23174%3B+Technologies&index=1&md5=a32a2cae6846c1f555e8ab3892c63eae Allurion® Technologies, a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced a major milestone for its AllurionTM Weight Loss Program with the launch of its new digital health offering featuring the Allurion TM Health Tracker smartwatch, Allurion® Connected Scale, Allurion® mobile app, and the Allurion TM Clinic Dashboard, the first in a series of new provider services that make up the Allurion TM Virtual Care Suite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005074/en/ The Allurion Connected Scale and Health Tracker measure all aspects of body composition including weight, body fat, muscle mass, as well as activity data such as steps, ex
Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index26.1.2021 12:35:00 CET | Press release
Takeda Pharmaceutical Company Limited(TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D capacity building, according to the Index. “This honor underscores Takeda’s commitment to prioritizing patient needs by ensuring access to our life-transforming treatments,” said Christophe Weber, Takeda president and chief executive officer. “As a purpose-driven company that puts the patient at the center of everything we do, we are committed to not just inventing medicines but making sure patients can access transformative therapies.” The AtM Index is a rigorous, biennial research project combining data-collection, verification, scoring and analysis
IFF Announces Preliminary Fourth Quarter & Full Year 2020 Financial Results26.1.2021 12:35:00 CET | Press release
IFF (NYSE:IFF), a leading innovator of taste, scent, and nutrition & ingredients, today announced preliminary, unaudited financial results for the quarter ended December 31, 2020. “In collaboration with DuPont’s financial announcement today, and in connection with the Exchange Offer related to our combination with DuPont Nutrition & Biosciences, we are providing preliminary financial results for the fourth quarter and full year 2020,” said IFF Chairman and CEO Andreas Fibig. “We expect to finish 2020 with results coming in ahead of our expectations despite continued challenges and complexity of the pandemic. This performance is a direct testament to the diversity of our portfolio, the essential nature of our products, and the resiliency of our global teams to continuously deliver for our customers.” Mr. Fibig continued, “With the completion of our merger with DuPont N&B now just days away, we continue to see multiple paths to strong value creation for all our stakeholders. Upon closing
Tilray® Selected by French National Agency to Supply GMP-Certified Medical Cannabis Products in France26.1.2021 12:00:00 CET | Press release
Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply Good Manufacturing Processes (GMP) certified medical cannabis products for experimentation in France. Tilray will supply GMP-produced medical cannabis products to serve patients in need for the duration of the French experiment (18-24 months), due to begin in the first quarter of 2021. Tilray products will be administered to qualifying patients in the French experiment, for whom existing treatments do not provide sufficient relief from their symptoms, and for therapeutic indications including: Neuropathic pain that is refractory to therapies currently available (drug or non-drug treatments); Certain forms of epilepsy that are drug-resistant; In certain persistent symptoms in oncology, related to cancer or anti-cancer treatment; In palliative care s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom